BioSpace News Archive

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for NERLYNX ® (neratinib) for the extended adjuvant

Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2020 financial results and business updates. First Quarter and Recent Highlights Validive Phase 2b/3 Clinical Trial Monopar, in response to the current COVID-19 pandemic and its effe

Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed treating patients in its Phase IV clinical tri

EG Group and the American Cancer Society have announced that their nationwide partnership to drive funding for life-saving programs and services provided by the American Cancer Society has generated $252,394 in charitable donations.

- Total 2020 Charitable Grants to Date Approach $17 Million - - Lifetime Giving Approaches $112 Million -

- ART enables greater workflow efficiency and lean sample management, supporting laboratories’ path towards total automation - The Procleix Panther System featuring ART improves system usability, increases operator walk-away time, and allows laboratories to select efficient configurations for current or future blood donor screening automation needs - The Grifols ART program is a cross-platform, long-term research and development initiative to enable ongoing advancements in la

MIM Software Inc., a leading global provider of medical imaging software, announced today that DocPanel has selected MIM Software’s Nuclear Medicine platform to strengthen its Oncological Imaging capability.

Today, the U.S. Food and Drug Administration is providing an update on the agency’s efforts to combat the extremely concerning actions by companies and individuals that are exploiting or taking advantage of widespread fear among consumers during the COVID-19 pandemic.

Collaborative effort helps drive funding for targeted clinical research needs in musculoskeletal healthcare

Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10ng/mL (link available here ) . Principal investigators Dr. Ronald T